1. < Home

Hematology/Oncology

Cultivating Relationship-Centered Care: Patient, Caregiver, and Provider Communication Preferences for and Experiences with Prognostic Conversations

Haverfield MC, Carrillo Y, Itliong JN, Ahmed A, Nash A, Singer A, Lorenz KA. Cultivating Relationship-Centered Care: Patient, Caregiver, and Provider Communication Preferences for and ...

By sjmartinez • May 11, 2023
Immunotherapy resistance driven by loss of NY-ESO-1 expression in response to transgenic adoptive cellular therapy with PD-1 blockade

Frankiw L, Singh A, Peters C, Comin-Anduix B, Berent-Maoz B, Macabali M, Shammaie K, Quiros C, Kaplan-Lefko P, Baselga Carretero I, Ribas A, Nowicki TS. ...

By sjmartinez • May 9, 2023
Brief Report: Safety and Antitumor Activity of Durvalumab Plus Tremelimumab in PD-(L)1-Monotherapy Pretreated, Advanced Non-Small Cell Lung Cancer: Results From a Phase 1b Clinical Trial

Brief Report: Safety and Antitumor Activity of Durvalumab Plus Tremelimumab in PD-(L)1-Monotherapy Pretreated, Advanced Non-Small Cell Lung Cancer: Results From a Phase 1b Clinical Trial

By sjmartinez • May 7, 2023
Patient and researcher stakeholder preferences for use of electronic health record data: a qualitative study to guide the design and development of a platform to honor patient preferences

By sjmartinez • May 5, 2023
High Recurrence For HPV-Positive Oropharyngeal Cancer With Neoadjuvant Radiotherapy To Gross Disease Plus Immunotherapy: Analysis From a Prospective Phase Ib/II Clinical Trial

Ma TM, Wong DJ, Chai-Ho W, Mendelsohn A, John MS, Abemayor E, Chhetri D, Sajed D, Dang A, Chu FI, Xiang M, Savjanji R, Weidhaas ...

By sjmartinez • May 5, 2023
Talimogene laherparepvec in combination with ipilimumab versus ipilimumab alone for advanced melanoma: 5-year final analysis of a multicenter, randomized, open-label, phase II trial

Chesney JA, Puzanov I, Collichio FA, Singh P, Milhem MM, Glaspy J, Hamid O, Ross M, Friedlander P, Garbe C, Logan T, Hauschild A, Lebbé ...

By sjmartinez • May 5, 2023
Exploratory Analysis of Patients With Gastric/Gastroesophageal Junction Adenocarcinoma With or Without Liver Metastasis From the Phase 3 RAINBOW Study

Ogata T, Narita Y, Wainberg ZA, Van Cutsem E, Yamaguchi K, Piao Y, Zhao Y, Peterson PM, Wijayawardana SR, Abada P, Chatterjee A, Muro K. ...

By sjmartinez • May 3, 2023
Patient Characteristics and Outcomes of Outpatient Tisagenlecleucel (tisa-cel) Recipients for B Cell Non-Hodgkin Lymphoma

Ahmed N, Wesson W, Mushtaq MU, Porter DL, Nasta SD, Brower J, Bachanova V, Hu M, Nastoupil LJ, Oluwole OO, Patel VG, Oliai C, Riedell ...

By sjmartinez • April 30, 2023
A 6-Week Program to Strengthen Resiliency Among Women With Metastatic Cancer: A Randomized Clinical Trial

Asher A, Shirazipour CH, Capaldi JM, Kim S, Diniz M, Jones B, Wertheimer J. A 6-Week Program to Strengthen Resiliency Among Women With Metastatic Cancer: ...

By sjmartinez • April 28, 2023
Beta-blockade enhances anthracycline control of metastasis in triple-negative breast cancer

Chang A, Botteri E, Gillis RD, Löfling L, Le CP, Ziegler AI, Chung NC, Rowe MC, Fabb SA, Hartley BJ, Nowell CJ, Kurozumi S, Gandini ...

By sjmartinez • April 27, 2023